Oramed Pharmaceuticals (ORMP) Other Accumulated Expenses (2021 - 2026)

Oramed Pharmaceuticals' Other Accumulated Expenses history runs 6 years deep, the most recent figure standing at $285000.0 for Q1 2026.

• Quarterly Other Accumulated Expenses changed N/A year-over-year to $285000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $285000.0 (changed N/A YoY) and the FY2025 annual result came in at $633000.0, up 87.28% from the prior year.
• Other Accumulated Expenses was $285000.0 for Q1 2026 at Oramed Pharmaceuticals, down from $633000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $633000.0 in Q4 2025 and bottomed at $5000.0 in Q4 2022.
• A 5-year average of $175083.3 and a median of $114500.0 in 2022 frame the typical range for Other Accumulated Expenses.
• Peak annual rise in Other Accumulated Expenses reached 1080.0% in 2023, while the deepest fall reached 55.64% in 2023.
• Oramed Pharmaceuticals' Other Accumulated Expenses stood at $5000.0 in 2022, then jumped by 1080.0% to $59000.0 in 2023, then soared by 472.88% to $338000.0 in 2024, then jumped by 87.28% to $633000.0 in 2025, then slumped by 54.98% to $285000.0 in 2026.
• Business Quant data shows ORMP's Other Accumulated Expenses at $285000.0 in Q1 2026, $633000.0 in Q4 2025, and $338000.0 in Q4 2024.